At March 31, 2024, Longboard’s cash, cash equivalents and short-term investments were approximately $321.0 million. “I am extremely encouraged by the totality of the bexicaserin data generated to date. The recently presented late-breaking data from the PACIFIC Study at AAN continues to support the potential of bexicaserin as a best-in-class and differentiated 5-HT2C agonist across a range of DEEs,” stated Kevin R. Lind, CEO. “We are pleased to have this compelling data set for our End of Phase 2 meeting with FDA and we look forward to initiating our global Phase 3 program before the end of the year. Additionally, we look forward to sharing other near-term milestones, including topline Phase 1 SAD data for LP659 this quarter and open-label extension data from the PACIFIC Study for bexicaserin in the second half of 2024.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Starbucks downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Longboard initiated with an Outperform at Baird on ‘best-in-class potential
- Longboard Pharmaceuticals initiated with an Outperform at Baird
- Longboard Pharmaceuticals to Reveal Bexicaserin Study Results
- Longboard Pharmaceuticals Embarks on Risky Global Expansion Amid Regulatory Hurdles and Market Instability